CRI's new website that seeks to engage, educate, and empower patients and their loved ones to learn more about cancer immunotherapy as a treatment option across numerous tumor types.
Cancer patients, donors, scientists, and other supporters all stand behind the Cancer Research Institute. Read their stories and learn about what motivates each of us to keep fighting against cancer.
By running in a marathon or hosting a bake sale, you can make a real difference for our scientists in the fight against cancer and allow them to bring newer immunotherapies to more patients.
We gratefully accept donations made in memory or in honor of a loved one. Your gift will be acknowledged to whomever you specify.
Hosted by CRI, EATI, CIMT, and AACR, register today for "Translating Science into Survival," on September 16-19, 2015, in New York City.
Curious about the latest developments in cancer immunotherapy research? Listen in as leading scientists discuss immune-based treatments across numerous cancer types in our free "Breakthroughs in Cancer Immunotherapy" webinar series.
When the Cancer Research Institute was founded in 1953, we knew then that immune-based treatments would transform cancer medicine. In more than six decades since, we've made numerous groundbreaking discoveries that have given more patients new hope today.
Donor generosity enables us to fund cutting-edge research all around the world. Our funded scientists from more than 20 countries have made and continue to make important discoveries about the immune system and how it can be harnessed to conquer cancer.
Through our scientists' inspiring work, the Cancer Research Institute and the people who support our mission have established a global footprint, and our impact in cancer research extends into nearly every top academic institution and medical center in the world.
We invite you to view our community network using the interactive map below. Filter to see where we are currently funding, or where we have funded ever. You can also see where our scientists are working now.